

BENSALEM, Pa.--([BUSINESS WIRE](#))-- [Law Offices of Howard G. Smith](#) announces that it is investigating potential claims on behalf of investors of Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (NYSE:PVCT). The investigation concerns possible violations of federal securities laws and focuses on certain statements issued by Provectus between December 17, 2013 and May 22, 2014, concerning the Company’s operations and financial prospects.

Provectus is a development-stage biopharmaceutical company engaged in developing pharmaceuticals for oncology and dermatology indications. The Company’s product line includes PV-10, which has completed a Phase II study for metastatic melanoma and a Phase I study for breast cancer, and is in various stages of clinical development for certain other cancer indications. The investigation is related to allegations that the Company misrepresented or failed to disclose material information concerning the status of PV-10 and preparations for a Phase III study of the drug.

On May 23, 2014, the Company announced that its application for a designation of PV-10 as “Breakthrough Therapy” was denied by the Food and Drug Administration. According to the Company, the FDA denied the designation because the agency’s review indicated that “the data upon which the Company based its request for designation of PV-10 as a Breakthrough Therapy for the treatment of patients with locally advanced cutaneous melanoma was insufficient to demonstrate substantial improvement over existing therapies.”

If you purchased Provectus shares between December 17, 2013 and May 22, 2014, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com